type here...
type here...
START FREE TRIAL

Tag: Healthcare

Healthcare

Technology & AIM&AHealthcareConsumer & RetailMiscellaneous

Merck’s $11 BillionBio-Techne Deal Looks Strategic, But The Debt Trade-Off Is REAL

M&A Ishan Majumdar -
Merck KGaA (ETR:MRK) has made a bold early move under new CEO Kai Beckmann. The German drug, chemicals, and...

AbbVie’s $11 Billion Eczema Gamble Is Bigger Than Skin

M&A Ishan Majumdar -
AbbVie Inc. (NYSE:ABBV) may be close to buying Apogee Therapeutics for about $10.9 billion in cash. That is a...

Moderna’s Flu Shot Won Over FDA Advisers—But Can It Win Back America?

Healthcare Ishan Majumdar -
Moderna (NASDAQ:MRNA) just landed a regulatory moment that people will argue about far beyond Wall Street. An FDA advisory...

Incyte Acquisition Watch: The $2 Billion Star Therapeutics Deal That Could Change Its Story

M&A Ishan M. -
Incyte Corporation (NASDAQ:INCY) is back in the biotech deal spotlight. The company is reportedly nearing an agreement to acquire...

Novo Nordisk Earnings Pre-Mortem: The Beat May Not Be Enough!

Healthcare Ishan M. -
Novo Nordisk reports first-quarter 2026 earnings on May 6, and the market is walking into the print with unusually...

Everyone Thinks Eli Lilly Is A Weight-Loss Stock. That’s The Trap

M&A Ishan Majumdar -
Eli Lilly (NYSE:LLY) is having one of those rare market moments where everyone thinks they understand the story. Weight-loss...

Amazon Earnings Pre-Mortem: THIS Is What’s Making Investors Nervous!!

Consumer & Retail Ishan M. -
Amazon reports earnings this week, and the setup looks strong on the surface. Consensus expects first-quarter revenue of roughly $177...

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

Healthcare Ishan Majumdar -
Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when...

Eli Lilly’s Foundayo & The GLP-1 Pivot From Innovation to Access Control!

Healthcare Ishan Majumdar -
Most coverage of Eli Lilly’s(NYSE:LLY) Foundayo launch has treated it like the next round in the company’s fight with...

The “Boring” Healthcare Stock Making A $5 Billion POWER MOVE!

M&A Ishan M. -
The market loves excitement. But money is often made in boredom. That is what makes Gilead Sciences (NASDAQ:GILD) such...

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

Healthcare Ishan M. -
There are biotech stories that look obvious, and then there are biotech stories that quietly change shape right in...

This “Broken” Biotech Just Forced Wall Street To Blink

M&A Ishan Majumdar -
Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle on Tuesday. What changed was the price investors were willing...
Load more

Merck’s $11 BillionBio-Techne Deal Looks Strategic, But The Debt Trade-Off Is REAL

M&A Ishan Majumdar -
Merck KGaA (ETR:MRK) has made a bold early move under new CEO Kai Beckmann. The German drug, chemicals, and...

AbbVie’s $11 Billion Eczema Gamble Is Bigger Than Skin

M&A Ishan Majumdar -
AbbVie Inc. (NYSE:ABBV) may be close to buying Apogee Therapeutics for about $10.9 billion in cash. That is a...

Moderna’s Flu Shot Won Over FDA Advisers—But Can It Win Back America?

Healthcare Ishan Majumdar -
Moderna (NASDAQ:MRNA) just landed a regulatory moment that people will argue about far beyond Wall Street. An FDA advisory...

Incyte Acquisition Watch: The $2 Billion Star Therapeutics Deal That Could Change Its Story

M&A Ishan M. -
Incyte Corporation (NASDAQ:INCY) is back in the biotech deal spotlight. The company is reportedly nearing an agreement to acquire...

Novo Nordisk Earnings Pre-Mortem: The Beat May Not Be Enough!

Healthcare Ishan M. -
Novo Nordisk reports first-quarter 2026 earnings on May 6, and the market is walking into the print with unusually...

Everyone Thinks Eli Lilly Is A Weight-Loss Stock. That’s The Trap

M&A Ishan Majumdar -
Eli Lilly (NYSE:LLY) is having one of those rare market moments where everyone thinks they understand the story. Weight-loss...

Amazon Earnings Pre-Mortem: THIS Is What’s Making Investors Nervous!!

Consumer & Retail Ishan M. -
Amazon reports earnings this week, and the setup looks strong on the surface. Consensus expects first-quarter revenue of roughly $177...

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

Healthcare Ishan Majumdar -
Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when...

Eli Lilly’s Foundayo & The GLP-1 Pivot From Innovation to Access Control!

Healthcare Ishan Majumdar -
Most coverage of Eli Lilly’s(NYSE:LLY) Foundayo launch has treated it like the next round in the company’s fight with...

The “Boring” Healthcare Stock Making A $5 Billion POWER MOVE!

M&A Ishan M. -
The market loves excitement. But money is often made in boredom. That is what makes Gilead Sciences (NASDAQ:GILD) such...

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

Healthcare Ishan M. -
There are biotech stories that look obvious, and then there are biotech stories that quietly change shape right in...

This “Broken” Biotech Just Forced Wall Street To Blink

M&A Ishan Majumdar -
Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle on Tuesday. What changed was the price investors were willing...

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 Baptista Research. All rights reserved.